Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain
- PMID: 33376181
- PMCID: PMC7778768
- DOI: 10.1136/bmjopen-2020-043400
Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain
Abstract
Introduction: In the USA, opioid analgesic use and overdoses have increased dramatically. One rapidly expanding strategy to manage chronic pain in the context of this epidemic is medical cannabis. Cannabis has analgesic effects, but it also has potential adverse effects. Further, its impact on opioid analgesic use is not well studied. Managing pain in people living with HIV is particularly challenging, given the high prevalence of opioid analgesic and cannabis use. This study's overarching goal is to understand how medical cannabis use affects opioid analgesic use, with attention to Δ9-tetrahydrocannabinol and cannabidiol content, HIV outcomes and adverse events.
Methods and analyses: We are conducting a cohort study of 250 adults with and without HIV infection with (a) severe or chronic pain, (b) current opioid use and (c) who are newly certified for medical cannabis in New York. Over 18 months, we collect data via in-person visits every 3 months and web-based questionnaires every 2 weeks. Data sources include: questionnaires; medical, pharmacy and Prescription Monitoring Program records; urine and blood samples; and physical function tests. Using marginal structural models and comparisons within participants' 2-week time periods (unit of analysis), we will examine how medical cannabis use (primary exposure) affects (1) opioid analgesic use (primary outcome), (2) HIV outcomes (HIV viral load, CD4 count, antiretroviral adherence, HIV risk behaviours) and (3) adverse events (cannabis use disorder, illicit drug use, diversion, overdose/deaths, accidents/injuries, acute care utilisation).
Ethics and dissemination: This study is approved by the Montefiore Medical Center/Albert Einstein College of Medicine institutional review board. Findings will be disseminated through conferences, peer-reviewed publications and meetings with medical cannabis stakeholders.
Trial registration number: ClinicalTrials.gov Registry (NCT03268551); Pre-results.
Keywords: HIV & AIDS; complementary medicine; pain management; statistics & research methods.
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Cannabis Use is Associated with Lower Odds of Prescription Opioid Analgesic Use Among HIV-Infected Individuals with Chronic Pain.Subst Use Misuse. 2018 Aug 24;53(10):1602-1607. doi: 10.1080/10826084.2017.1416408. Epub 2018 Jan 17. Subst Use Misuse. 2018. PMID: 29338578 Free PMC article. Clinical Trial.
-
Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial.BMJ Open. 2018 Apr 20;8(4):e019559. doi: 10.1136/bmjopen-2017-019559. BMJ Open. 2018. PMID: 29678969 Free PMC article. Clinical Trial.
-
Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol.BMJ Open. 2022 Jun 9;12(6):e064457. doi: 10.1136/bmjopen-2022-064457. BMJ Open. 2022. PMID: 35680252 Free PMC article.
-
Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review.Syst Rev. 2020 Jul 28;9(1):167. doi: 10.1186/s13643-020-01425-3. Syst Rev. 2020. PMID: 32723354 Free PMC article.
-
Perspectives on cannabis as a substitute for opioid analgesics.Pain Manag. 2019 Mar 1;9(2):191-203. doi: 10.2217/pmt-2018-0051. Epub 2019 Jan 25. Pain Manag. 2019. PMID: 30681029 Review.
Cited by
-
First-Year Trajectories of Medical Cannabis Use Among Adults Taking Opioids for Chronic Pain: An Observational Cohort Study.Pain Med. 2021 Dec 11;22(12):3080-3088. doi: 10.1093/pm/pnab257. Pain Med. 2021. PMID: 34411246 Free PMC article.
-
Pain catastrophizing and mental health phenotypes in adults with refractory chronic pain: A latent class analysis.J Psychiatr Res. 2022 Jan;145:102-110. doi: 10.1016/j.jpsychires.2021.12.001. Epub 2021 Dec 2. J Psychiatr Res. 2022. PMID: 34890916 Free PMC article. Review.
-
"It doesn't make any sense to even try": the disruptive impact of COVID-19's first wave on people with chronic pain using medical cannabis in New York.J Cannabis Res. 2023 Mar 29;5(1):10. doi: 10.1186/s42238-023-00180-1. J Cannabis Res. 2023. PMID: 36978185 Free PMC article.
-
Increasing Access to Safe Medical Cannabis: Establishment of a Medical Cannabis Program in a Safety-Net Academic Medical Center.NEJM Catal Innov Care Deliv. 2022 Feb;3(2):10.1056/cat.21.0373. doi: 10.1056/cat.21.0373. Epub 2022 Jan 19. NEJM Catal Innov Care Deliv. 2022. PMID: 36172004 Free PMC article.
-
Factors Associated with Medical Cannabis Use After Certification: A Three-Month Longitudinal Study.Cannabis Cannabinoid Res. 2024 Jun;9(3):e859-e869. doi: 10.1089/can.2022.0248. Epub 2023 Mar 24. Cannabis Cannabinoid Res. 2024. PMID: 36961410 Free PMC article.
References
-
- Breitbart W, Dibiase L. Current perspectives on pain in AIDS. Oncology 2002;16:964–8. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials